書誌事項
- タイトル別名
-
- Development of Epalrestat (Kinedak): Aldose Reductase Inhibitor.
- トウニョウビョウ ガッペイショウ ノ チリョウヤク アルドース カンゲン コウ
この論文をさがす
説明
It is believed that the aldose reductase (AR, EC 1.1.21), the initial enzyme of sorbitol pathway, plays a significant role in the initiation of diabetic complications. In a search for AR inhibitors, a series of 4-oxo-2-thioxothiazolidine-3-acetic acid derivatives was synthesized and showed the inhibitory activity against AR. (Z, E) -5- (2-Methyl-3-phenyl-2-propenylidene) -4-oxo-2-thioxothiazolidine-3-acetic acid (epalrestat) prevented the accumulation of sorbitol in rat sciatic nerve and rat blood cell, and improved motor nerve conduction velocity of diabetic rats. In clinical studies, epalrestat has shown the improvements in nerve function and subjective symptoms. In Japan, epalrestat was introduced on the market in January, 1992.
収録刊行物
-
- 有機合成化学協会誌
-
有機合成化学協会誌 55 (7), 651-657, 1997
公益社団法人 有機合成化学協会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282680254595328
-
- NII論文ID
- 10009337869
-
- NII書誌ID
- AN0024521X
-
- ISSN
- 18836526
- 00379980
-
- NDL書誌ID
- 4248952
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDLサーチ
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可
